Semax vs VIP
Both Semax and VIP are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Semax
Evidence BSemax (MEHFPGP)
A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
View full Semax profile →VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Side-by-Side
| Attribute | Semax | VIP |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved in US — approved in Russia for stroke and cognitive disorders | Not FDA-approved — investigational; ongoing trials for sarcoidosis |
| Typical Dose | 200–600 mcg intranasal, morning | 50 mcg intranasal, 4 times daily (CIRS protocols) |
| Clinics Indexed | 89 | 24 |
| Categories | cognitive, neuroprotection | anti-inflammatory, neuroprotection |
Key reported benefits — Semax
- ✓BDNF increase
- ✓Enhanced focus
- ✓Memory improvement
- ✓Neuroprotection
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.